Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $9.90.

Shares of CRBP stock opened at $11.30 on Monday. Corbus Pharmaceuticals has a 52-week low of $5.67 and a 52-week high of $61.90. The stock has a market cap of $137.62 million, a price-to-earnings ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Silver Gas Price Forecast: Drops Below Key MAs, Bearish Continuation LoomsMon, 13 Jan 2025 21:33:27 GMT Natural Gas Price Forecast: Failed Breakout Signals Bearish ShiftMon, 13 Jan 2025 21:29:20 ...

Buy CRBP near 5.96 target 20.19 stop loss @ 5.94 Details The technical summary data tells us to buy CRBP near 5.96 with an upside target of 20.19. This data also tells us to set a stop loss @ 5.94 to ...

As of January 22 at 9:42:39 AM EST. Market Open.